CD274 and small cell lung carcinoma: However, the advantage of cost-effectiveness has not been identified in PD-L1-positive advanced ESCC patients, which primarily attributed to better survival improvements of serplulimab plus chemotherapy in extensive-stage small-cell lung cancers.